MIT Spinoff Closes $5M Series A Funding Round With Investments from Battelle Ventures
February 27, 2009
ShareThisHepregen Corp., a biotechnology company developing a platform for reducing the liver toxicity caused by approved drugs, has closed its series A funding with commitment of the final $2 million in a total $5 million investment from Battelle Ventures and its funding partner, Innovation Valley Partners. The company initially received $3 million in September of last year from Battelle Ventures and Innovation Valley Partners.
Hepregen’s platform is based on technology developed by Sangeeta Bhatia, an associate professor in the Harvard-MIT Division of Health Sciences and Technology (HST) and MIT’s Department of Electrical Engineering and Computer Science. Hepregen was co-founded by Bhatia and her colleague within the HST division, Salman Khetani. It combines tissue engineering and micro fabrication to create optimized, precise and organized micro livers that aide in toxicity screening and a new platform for drug discovery.
To read the full story, see Genetic Engineering & Biotechnology News
http://www.genengnews.com/news/bnitem.aspx?name=50186941